DV 1179

Drug Profile

DV 1179

Alternative Names: DV1079; DV1179

Latest Information Update: 21 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Class Oligonucleotides
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Inflammation
  • Discontinued Systemic lupus erythematosus

Most Recent Events

  • 21 Dec 2015 Phase-I development for Inflammation and Autoimmune disorders is ongoing in USA
  • 28 Nov 2014 Dynavax Technologies regains full rights to DV 1179
  • 07 Aug 2014 Adverse events data from a phase Ib/IIa trial in Systemic lupus erythematosus released by Dynavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top